(Q42672585)

4 November 2017

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. (English)

1 reference

4 November 2017

0 references

1 reference

1 reference

1

Fred Poordad

0 references

author name string

Eric Lawitz

2

1 reference

4 November 2017

Mitchell L Shiffman

3

1 reference

4 November 2017

Tarek Hassanein

4

1 reference

4 November 2017

Andrew J Muir

5

1 reference

4 November 2017

Bruce R Bacon

6

1 reference

4 November 2017

Jamie Heise

7

1 reference

4 November 2017

Deanine Halliman

8

1 reference

4 November 2017

Eric Chun

9

1 reference

4 November 2017

Janet Hammond

10

1 reference

4 November 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

4 November 2017

1 reference

4 November 2017

52

1 reference

4 November 2017

4

1 reference

4 November 2017

1208-1215

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

4 November 2017

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

7 January 2021

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

7 January 2021

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

7 January 2021

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

1 reference

7 January 2021

Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C.

1 reference

7 January 2021

Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

1 reference

7 January 2021

Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

1 reference

7 January 2021

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.

1 reference

7 January 2021

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

1 reference

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

7 January 2021

Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy

1 reference

7 January 2021

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

1 reference

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

7 January 2021

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

1 reference

7 January 2021

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23827

1 reference

4 November 2017

1 reference